PTN

PTN

USD

Palatin Technologies Inc. Common Stock

$0.094-0.009 (-8.641%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$0.103

Hoch

$0.107

Tief

$0.087

Volumen

0.34M

Unternehmensfundamentaldaten

Marktkapitalisierung

2.4M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.77M

Börse

ASE

Währung

USD

52-Wochen-Spanne

Tief $0.035Aktuell $0.094Hoch $2.13

Ähnliche Nachrichten

PR Newswire

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...

Mehr anzeigen
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
PR Newswire

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor...

Mehr anzeigen
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
PR Newswire

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Mehr anzeigen
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
PR Newswire

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Mehr anzeigen
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide